Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Beam Therapeutics
BEAM-302 Data for AATD: Promising Results at ERS Congress
September 8, 2026
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
September 1, 2026
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
August 31, 2026
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
August 4, 2026
Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
July 23, 2026
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration
June 18, 2026
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
May 26, 2026
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
May 25, 2026
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
May 25, 2026
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
May 25, 2026
1
2
Next Page
→